Researchers presenting at the 2018 ASCO Genitourinary Cancers Symposium compared the costs associated with two different approaches to management of low-risk prostate cancer and gave a recommendation toward a value-based care model.
A study soon to published found that palliative care for patients with ovarian cancer was often provided later than recommended in national guidelines.
A recent study evaluated the impact of a geriatric oncology clinic on cancer treatment plans and supportive care in older adults with genitourinary cancers.
The FDA has approved a hormone-based chemotherapy in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
A cost-effectiveness analysis presented at the 2018 Genitourinary Cancers Symposium examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.
Human epidermal growth factor receptor 2 may be a potential marker of poor prognosis in patients with unclassified ovarian cancer, according to a recent meta-analysis.
Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
An online stress management program may significantly improve the quality of life for patients newly diagnosed with cancer, according to a recent study.